NeuroDerm (NASDAQ:NDRM) Earning Somewhat Favorable News Coverage, Study Shows
Media stories about NeuroDerm (NASDAQ:NDRM) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NeuroDerm earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have impacted Accern Sentiment’s analysis:
- Roth Capital Downgrades NeuroDerm Ltd. (NDRM) to Neutral (americanbankingnews.com)
- NeuroDerm Ltd. (NDRM) is stand at $38.70 While Inogen, Inc. (INGN) valued at $94.38 per share – Stocks Gallery (stocksgallery.com)
- NeuroDerm Announces Extraordinary General Meeting of Shareholders to Approve Acquisition by Mitsubishi Tanabe Pharma Corporation (finance.yahoo.com)
- Zacks: Brokerages Expect NeuroDerm Ltd. (NASDAQ:NDRM) to Post -$0.47 Earnings Per Share (americanbankingnews.com)
- Neuroderm Ltd (NDRM) MFI Reading Under the Microscope – Evergreen Caller (evergreencaller.com)
Several equities research analysts recently commented on the stock. Roth Capital lowered shares of NeuroDerm from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $33.00 to $39.00 in a report on Wednesday. BidaskClub raised shares of NeuroDerm from a “sell” rating to a “hold” rating in a report on Tuesday, July 25th. Raymond James Financial, Inc. lowered shares of NeuroDerm from an “outperform” rating to a “market perform” rating and set a $39.00 price target for the company. in a report on Monday, July 24th. Deutsche Bank AG started coverage on shares of NeuroDerm in a research note on Friday, July 21st. They set a “buy” rating and a $47.00 target price on the stock. Finally, Zacks Investment Research cut shares of NeuroDerm from a “hold” rating to a “sell” rating in a research note on Saturday, July 15th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $44.13.
Shares of NeuroDerm (NDRM) traded down 0.13% on Thursday, hitting $38.60. 1,290,371 shares of the stock traded hands. The company has a market cap of $1.02 billion, a PE ratio of 26.08 and a beta of 0.79. NeuroDerm has a 12 month low of $15.20 and a 12 month high of $38.85. The firm’s 50 day moving average is $31.35 and its 200-day moving average is $26.69.
NeuroDerm (NASDAQ:NDRM) last announced its earnings results on Thursday, May 11th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.13. Equities analysts predict that NeuroDerm will post ($2.00) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/03/neuroderm-nasdaqndrm-earns-coverage-optimism-score-of-0-14-updated-updated-updated.html.
NeuroDerm Company Profile
NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.
Receive News & Stock Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related stocks with our FREE daily email newsletter.